BRM Stock Overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 5/6 |
Bristol-Myers Squibb Company Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$41.70 |
52 Week High | US$63.50 |
52 Week Low | US$41.54 |
Beta | 0.39 |
1 Month Change | -15.07% |
3 Month Change | -9.05% |
1 Year Change | -30.96% |
3 Year Change | -18.24% |
5 Year Change | -3.87% |
Change since IPO | -8.71% |
Recent News & Updates
Recent updates
Shareholder Returns
BRM | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | -7.8% | 2.3% | 0.5% |
1Y | -31.0% | -28.6% | 1.3% |
Return vs Industry: BRM underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: BRM underperformed the German Market which returned 2.3% over the past year.
Price Volatility
BRM volatility | |
---|---|
BRM Average Weekly Movement | 4.1% |
Pharmaceuticals Industry Average Movement | 6.6% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BRM has not had significant price volatility in the past 3 months.
Volatility Over Time: BRM's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1887 | 34,100 | Chris Boerner | www.bms.com |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Bristol-Myers Squibb Company Fundamentals Summary
BRM fundamental statistics | |
---|---|
Market cap | €84.45b |
Earnings (TTM) | -€5.73b |
Revenue (TTM) | €42.45b |
2.0x
P/S Ratio-14.7x
P/E RatioIs BRM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BRM income statement (TTM) | |
---|---|
Revenue | US$45.53b |
Cost of Revenue | US$10.88b |
Gross Profit | US$34.65b |
Other Expenses | US$40.80b |
Earnings | -US$6.15b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 26, 2024
Earnings per share (EPS) | -3.03 |
Gross Margin | 76.10% |
Net Profit Margin | -13.50% |
Debt/Equity Ratio | 135.1% |
How did BRM perform over the long term?
See historical performance and comparison